Clinical Trial Update: A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations [Phase 2]

View source ↗

Summary

Phase 2 trial of ASP8273 in EGFR-mutant, EGFR-TKI–naïve non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASP8273

Snippet

Sponsor: Astellas Pharma Inc | Conditions: EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations | Phase 2 | Status: TERMINATED